Related Articles
Research
Leerink Partners Downgrades Fulcrum Therapeutics to Market Perform From Outperform, Adjusts PT to $4 From $24
Fulcrum Therapeutics (FULC) has an average rating of hold and mean price target of $9.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$FULC
Research
Jefferies Downgrades StandardAero to Hold From Buy, Adjusts Price Target to $30 From $34
StandardAero (SARO) has an average rating of buy and mean price target of $35.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$SARO
Research
Evercore ISI Upgrades Guardant Health to Outperform From In Line, Adjusts PT to $160 From $95
Guardant Health (GH) has an average rating of overweight and mean price target of $134.80, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
$GH